Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBT Margin (2017 - 2025)

Organogenesis Holdings has reported EBT Margin over the past 9 years, most recently at 28.11% for Q4 2025.

  • Quarterly results put EBT Margin at 28.11% for Q4 2025, up 2002.0% from a year ago — trailing twelve months through Dec 2025 was 8.33% (up 891.0% YoY), and the annual figure for FY2025 was 8.33%, up 891.0%.
  • EBT Margin for Q4 2025 was 28.11% at Organogenesis Holdings, up from 14.03% in the prior quarter.
  • Over the last five years, EBT Margin for ORGO hit a ceiling of 28.11% in Q4 2025 and a floor of 29.74% in Q1 2025.
  • Median EBT Margin over the past 5 years was 7.31% (2022), compared with a mean of 3.88%.
  • Biggest five-year swings in EBT Margin: skyrocketed 3626bps in 2021 and later tumbled -2579bps in 2025.
  • Organogenesis Holdings' EBT Margin stood at 14.77% in 2021, then plummeted by -49bps to 7.58% in 2022, then crashed by -124bps to 1.8% in 2023, then soared by 549bps to 8.1% in 2024, then skyrocketed by 247bps to 28.11% in 2025.
  • The last three reported values for EBT Margin were 28.11% (Q4 2025), 14.03% (Q3 2025), and 11.72% (Q2 2025) per Business Quant data.